What are the treatment options for patients with severe Alzheimer's disease?

CNS Drugs

Volumn 18, Issue 9, 2004, Pages 575-583

  Voisin, Thierry ^a   Reynish, Emma ^a   Portet, Florence ^b   Feldman, Howard ^c   Vellas, Bruno ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMIC ACID; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; MEMANTINE; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENANTHRENE; PIPERIDINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ATTENTION; CAREGIVER; CLINICAL TRIAL; COGNITION; DISEASE SEVERITY; EUROPE; HUMAN; MEDICAL SPECIALIST; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; REVIEW; SIDE EFFECT;

ALZHEIMER DISEASE; CARBAMATES; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; GALANTAMINE; HUMANS; MEMANTINE; PHENYLCARBAMATES; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 3242669518     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418090-00003     Document Type: Review

References (34)

1. Canadian Study of Health and Aging Working Group. Patterns of caring for people with dementia in Canada. Can J Aging 1994; 13: 470-87
2. Schmitt FA, Cragar D, Ashford JW, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm 2002; 62: S135-48
3. Feldman H, Gauthier S, Hecker J, et al. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20
4. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is these a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16 (7): 653-66
5. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999 Feb; 14 (2): 135-46
6. Davis KL, Mohs RC, Marin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999; 281: 1401-6
7. Jones RW. Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? Int J Geriatr Psychiatry 2003; 18: S7-S13
8. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18 (Suppl.): S1-5
9. Mega MS, Masterman DM, O'Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999; 56: 1388-93
10. Dekosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002; 51 (2): 145-55
11. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45
12. Corey-Bloom J, Anand R, Veach J. A randomised trial evaluating the efficacy and safety of rivastigmine tartrate, a new acetylcholinesterase inhibitor in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65
13. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine US A-10 Study Group. Neurology 2000; 54: 2269-76
14. Ogura H, Kosasa T, Kuriya Y, et al. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 2000; 22: 609-13
15. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44
16. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbance in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2000; 97 (11): 6037-42
17. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95
18. Polinsky RJ. Clinical pharmacology of rivastigmine: a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998; 20 (4): 634-47
19. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8
20. Cummings J, Anand R, Koumaras B, et al. Rivastigmine provides behavioral benefits to AD patients residing in a nursing home: findings from a 26-week trial [abstract]. Neurology 2000; 54: A468
21. Bullock R, Moulias R, Steinwachs K-C, et al. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer's disease: a European, open-label, multicentre study [abstract]. Int Psychogeriatr 2001; 13 Suppl. 2: P-248
22. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6
23. Nordberg A, Darreh-Shori T, Svensson A, et al. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment [abstract]. J Neurol Sci 2001; 187 Suppl. 1: P0144
24. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantaminein AD. Neurology 2000; 54: 2269-76
25. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial Galantamine International-1 study group. BMI 2000 Dec 9; 321: 1445-9
26. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54 (12): 2261-8
27. Feldman H, Gauthier S, Hecker I, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737-44
28. Tariot PN, Cummings IL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001 Dec; 49 (12): 1590-9
29. Blesa R, Davidson M, Kurz A, et al. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003; 15 (2): 79-87
30. Doraiswamy PM, Krishnan KR, Anand R, et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002 May; 26 (4): 705-12
31. Reisberg B, Doody R, Stoffler A, et al. A randomized placebo-controlled study of memantine, an uncompetitive NMDA antagonist, in patients with moderate to severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41
32. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 Jan 21; 291 (3): 317-24
33. Bullock R, Hammond G. Realistic expectations: the management of severe Alzheimer disease. Alzheimer Dis Assoc Disord 2003 Jul-Sep; 17 Suppl 3: S80-5
34. Gillette S, Nourhashemi F, Andrieu S, et al. The REAL.FR Research program on Alzheimer's Disease and its management: methods and preliminary results. J Nutr Health Aging 2003; 2: 91-6